Prior CTLA-4 Inhibition May Influence Response to PD-1 Inhibitors in Patients With Advanced Melanoma
Source: The Asco Post, April 2023
Researchers have found that responses to PD-1 inhibitor treatment in patients with advanced melanoma may depend on whether they had received previous treatment with CTLA-4 inhibitors, according to a new study published by Campbell et al in Cancer Cell.
“In our large set of data, features that have been used to predict responses to PD-1 [inhibitor] therapy—often called biomarkers—related to the presence of certain immune cell types in the tumor and the genetic profile of the tumors themselves were modified by a patient’s treatment history,” emphasized lead study author Katie Campbell, PhD, a postdoctoral research fellow in the Department of Hematology/Oncology at the University of California, Los Angeles (UCLA) Jonsson Comprehensive Cancer Center.
Background
Typical treatments for patients with advanced melanoma include immunotherapies such as PD-1 inhibitors and CTLA-4 inhibitors, either in combination or as monotherapies.